| EN

Simcere Announces Appointment of Mr. Zhou Gaobo as Chief Investment Officer

Release time:2022-01-18


On January 17, 2022, Simcere Pharmaceutical Group (2096.HK) announced the appointment of Mr. Zhou Gaobo as Chief Investment Officer. He will be in charge of the company's innovative drug investment and business development, establishing of new investment platform, as well as the investment strategic planning and practice. He has officially taken office since January 17.


Mr. Ren Jinsheng, Chairman and CEO of Simcere said, “Welcome Mr Zhou Gaobo to join the company's management team. In order to fulfill our corporate mission of providing patients with better medicines, Simcere is in the process of rapid transformation towards pharmaceutical innovation. Mr. Zhou Gaobo has extensive experience in strategy planning, management, and commercial consultancy. With his strategic vision,deep insight and proven leadership in the global biopharmaceutical industry, I believe he will further strengthen Simcere's management team and adding momentum to the company’s future development."


Mr Zhou Gaobo said, "I am honored to serve as the Chief Investment Officer of Simcere. The company’s commitment and accelerated progress towards innovation are highly encouraging. I look forward to working with Simcere colleagues to further drive strategic investments in innovation so as to provide patients with more efficient, differentiated, and innovative treatment solutions."


Before joining Simcere, Mr. Gaobo Zhou was a Partner at McKinsey and Company and co-leader of the Greater China Healthcare practice. He has fifteen years of experience in management consulting in the healthcare industry. He worked with leading pharmaceutical, biotechnology, medical device, and life science investment companies on a broad range of topics in the China Healthcare Reform and innovation context, including strategy, business model innovation, digital transformation, and investment and partnership. He also built the largest healthcare management consulting team in the industry. Previously, he also worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug development.


Mr. Gaobo Zhou holds an MBA from Duke University, a Master's Degree in Biochemistry from the University of Maryland and a Bachelor’s Degree in Genetics from Fudan University.